Literature DB >> 30865538

THE INFLUENCE OF SURGICAL EXTENT AND PARAFIBROMIN STAINING ON THE OUTCOME OF PARATHYROID CARCINOMA: 20-YEAR EXPERIENCE FROM A SINGLE INSTITUTE.

Ya Hu, Yalan Bi, Ming Cui, Xiang Zhang, Zhe Su, Mengyi Wang, Surong Hua, Quan Liao, Yupei Zhao.   

Abstract

Objective: Parathyroid carcinoma (PC) is a rare endocrine malignancy with a poor prognosis. The optimal surgical procedure and prognostic factors for PC remain controversial.
Methods: Clinical information and parafibromin staining results from 53 patients with PC were reviewed retrospectively from 1997 to 2018. Immunohistochemical staining for parafibromin was performed on formalin-fixed, paraffin-embedded tissue samples. The influence of clinical parameters, surgical procedure, and parafibromin staining of tumor tissues on prognosis were evaluated.
Results: A total of 53 patients with PC were enrolled in this study. The male to female ratio was 1.94:1. En bloc resection was performed as initial surgery for 18 patients (34.0%), and 35 patients (66.0%) underwent local resection. Parafibromin staining was negative in the tumor tissues of 24 PC patients (45.3%). Thirty-three patients suffered from local recurrence or distant metastasis, and overall mortality was 16/53 at a median follow-up time of 80 months (range, 7 to 282 months). Cox proportional hazards analysis showed that negative parafibromin staining (hazard ratio [HR], 4.13; 95% confidence interval [CI], 1.73 to 9.87; P = .001) was related to recurrence or metastasis and that age >50 years (HR, 5.66; 95% CI, 1.58 to 20.31; P = .008) was related to mortality. The extent of resection was not related to recurrence or overall survival.
Conclusion: The majority of PC patients have a relatively long survival with multiple recurrences. Absence of parafibromin staining was a factor that influenced PC recurrence. The main factor influencing PC outcomes may be the biological characteristics rather than surgical extent. Abbreviations: CI = confidence interval; DFS = disease-free survival; HR = hazard ratio; OS = overall survival; PC = parathyroid carcinoma; WHO = World Health Organization.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 30865538     DOI: 10.4158/EP-2018-0538

Source DB:  PubMed          Journal:  Endocr Pract        ISSN: 1530-891X            Impact factor:   3.443


  5 in total

1.  Mortality factors in recurrent parathyroid cancer: a pooled analysis.

Authors:  Wen-Hsuan Tsai; Yi-Hong Zeng; Chun-Chuan Lee; Ming-Chieh Tsai
Journal:  J Bone Miner Metab       Date:  2022-02-20       Impact factor: 2.626

2.  A Nomogram Predicting the Overall Survival and Cancer-Specific Survival in Patients with Parathyroid Cancer: A Retrospective Study.

Authors:  Mei Tao; Shuyan Luo; Xiaoming Wang; Meng Jia; Xiubo Lu
Journal:  Front Endocrinol (Lausanne)       Date:  2022-05-19       Impact factor: 6.055

3.  The Use and Benefit of Adjuvant Radiotherapy in Parathyroid Carcinoma: A National Cancer Database Analysis.

Authors:  Jessica Limberg; Dessislava Stefanova; Timothy M Ullmann; Jessica W Thiesmeyer; Sarina Bains; Toni Beninato; Rasa Zarnegar; Thomas J Fahey; Brendan M Finnerty
Journal:  Ann Surg Oncol       Date:  2020-07-13       Impact factor: 5.344

4.  Patterns and Predictors of Cervical Lymph Node Metastasis in Parathyroid Carcinoma.

Authors:  Ya Hu; Ming Cui; Xiaoyan Chang; Ou Wang; Tianqi Chen; Jinheng Xiao; Mengyi Wang; Surong Hua; Quan Liao
Journal:  Cancers (Basel)       Date:  2022-08-19       Impact factor: 6.575

Review 5.  The roles of the tumor suppressor parafibromin in cancer.

Authors:  Hua-Chuan Zheng; Hang Xue; Cong-Yu Zhang
Journal:  Front Cell Dev Biol       Date:  2022-09-21
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.